Intense Pulsed Light (IPL)

 dry-eye-syndrome-treatment

What is E-Eye?

E-Eye has been specifically designed for treating dry eye due to meibomian gland dysfunction (MGD). The device works by producing a specifically calibrated series of intense pulsed light (IPL). These light pulses are precisely set at a specific energy and frequency that stimulates the Meibomian glands and helps them recover their function.

Accordingly, the E-Eye IPL device is useful in the treatment and prevention of dry eye syndrome.

Fast and easy treatments

Treatment only takes three minutes. No preheating all maintenance as required other than cleaning the applicator.

The manufacturer ensures that specialised training is provided to the optometrists and ophthalmologists applying the treatment using the E-Eye device.

The E-Eye also includes an integrated display with a step-by-step validation process to ensure safety in use.

E-Eye has a two-year warranty and 90 day money back guarantee for clinics.

dryeyesyndrome

Treatment Protocol

1. Prior to treatment

The eyecare specialist will review the patients dry eye condition and assess their skin phototype from grade I (fair skin) to grade IV (black skin).

2. During treatment

- Remove all make up from the skin.
- Fit the patient with protective goggles.
- Fit the operator with protective glasses.
- Apply conductive gel beneath the eyelid area to ensure even spreading of pulsed light during treatment.
- Apply 4 or 5 flashes beneath the eyelid area.

3. After treatment

Treatment is non invasive and patients typically experience relief within a few minutes.

4. Contraindications

General contraindications apply regarding ILP devices such as not taking medicines that increase photo-sensitivity, and not flashing near moles, birthmarks or tattoos.

For the best results, treatment should be applied on day 1, day 15, and day 45, and then subsequently as needed.

Medically certified

E-Eye has a Medical CE certification in Europe and is also a registered medical device listed under the TGA in Australia and WAND in New Zealand.